3:43 PM
Sep 13, 2017
 |  BC Extra  |  Clinical News

Lexicon's sotagliflozin increases risk of ketoacidosis in Phase III

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) was off $0.98 to $13.76 on Wednesday after reporting that sotagliflozin (SAR439954) increased the risk of diabetic ketoacidosis (DKA) in the Phase III inTandem3 trial to treat Type I diabetes, which met its primary endpoint in June. The company said partner Sanofi (Euronext:SAN; NYSE:SNY) plans to submit global regulatory applications for the product to treat Type I diabetes next half (see BioCentury Extra, June 9).

In inTandem3, the rate of...

Read the full 366 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >